China News Online, July 19 (Reporter Chen Jing) Multiple myeloma ("MM" for short) is one of the common malignant tumors of the blood system, with an increasing incidence year by year and a trend of younger generation.
Professor Wang Jianxiang, deputy dean of the Hospital of Hematology of the Chinese Academy of Medical Sciences, emphasized in an interview here on the 19th that even if the "MM" is controlled, strengthening the concept of "long-term medication and regular review" is still the top priority for patients.
He pointed out that long-term disease-free survival can only be achieved by reducing the number of relapses as much as possible.
At the just-concluded First China Blood East Summit and Deqi Blood Summit, Wu Depei, director of the Department of Hematology at the First Affiliated Hospital of Soochow University, introduced that gene mutations have a driving role in the relapse of "MM", but many relapses are caused by irregular treatment. For example, the patient did not undergo consolidation and maintenance treatment after remission. This is also an important factor affecting the prognosis. Repeated relapses will make the prognosis worse and worse.
It is reported that at the first China Blood East Summit and Deqi Blood Summit Forum, nearly 200 well-known experts and scholars from the field of hematology and tumors in China gathered together to focus on the latest diagnosis and treatment progress and hot topics in practice in the field of hematology and tumors, and discuss cutting-edge trends and development of.
It is understood that currently, for "MM", the traditional Chinese treatment method is mainly "chemotherapy", facing the dilemma of incurable treatment, unsatisfactory patient prognosis, and inevitable recurrence. There is an urgent need for effective treatment methods and new drugs to improve the cure rate and clinical practice. effect.
Professor Shen Zhixiang, a tenured professor of internal medicine at Ruijin Hospital affiliated to Shanghai Jiaotong University, pointed out in an interview with reporters: “In China, patients with multiple myeloma who have received multiple drug treatments and still relapse face the clinical dilemma that no medicine is available. Facing this category For the population, the availability of more and more convenient treatment drugs has become the urgent expectation of clinicians and patients."
The reporter learned that the purpose of this forum is to promote academic exchanges and cooperation in the field of hematology in China, realize the sharing of professional scientific research and clinical treatment information and the docking of results, and promote standardized comprehensive treatment and discipline construction and development.
It is reported that there are many new lymphoma patients in China every year.
Professor Ma Jun, director of the Harbin Institute of Hematology and Tumor, said: “At present, large domestic hospitals are constantly exploring new models of standardized diagnosis and treatment of lymphoma, and more and more new drugs are entering the clinic from the basics. For those who are not suitable for transplantation or recurrence after transplantation. For about 60% of the relapsed/refractory patients, the breakthrough of new drugs may be an important starting point for solving this clinical dilemma."
Professor Zhao Weilai, deputy dean of Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, and many other experts told reporters that the second-line standard treatment for patients with refractory relapsed diffuse lymphoma is salvage chemotherapy followed by autologous stem cell transplantation, but more than half of the cases are still Relapsed and refractory patients are not suitable for transplantation or relapse after transplantation. The treatment of these patients is currently a clinical problem.
Professor Liu Qifa, director of the Institute of Hematology of Southern Medical University, said bluntly that the problem of small-molecule targeted drugs today is that they are expensive, and patients need to continue to use the drugs, and the financial burden is heavy.
He believes that more drugs can be localized and localized in order to achieve "affordable and sustained medication."
As a hematologist, he hopes that more and more affordable and effective new drugs will bring "life" to patients.
(Finish)